EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Frequency of multi-vessel disease and its association with N Terminal-Pro Brain Natriuretic Peptide Levels among patients with First ST-Elevation Myocardial Infarction.

Kaleem Ullah Sheikh, Abeer Sarfaraz, Sana Sarfaraz, Aemon Zehra, Mohad Amir, Haad Amir

Nepalese Heart Journal · 2024

DOI: 10.3126/nhj.v21i1.65664 ↗
AbstractBibliografische Angaben

Abstract

Background and Aims: To determine the frequency of multi-vessel disease among patients with First ST-Elevation Myocardial Infarction and to identify the cutoff value of N Terminal-Pro Brain Natriuretic Peptide (NT-proBNP) for diagnosis of multi-vessel disease. Methodology: A descriptive cross-sectional study was conducted in the Department of Cardiology at a tertiary care hospital from September 2021 to February 2022. The study included 150 patients who presented to the emergency room with first ST-elevation myocardial infarction and preserved ejection fraction. NT-proBNP levels were tested within 12 hours of hospital admission. The severity of coronary artery disease was assessed by the number of vessels affected labeled, the luminal diameter narrowing and the syntax score. Results: The mean age of participants was 60.60±11.1 years. 76% were men, 53.3% of the participants had hypertension, 44% had type 2 diabetes, and 14% were smokers. The mean BMI of the patients was 27.86±3.86. The mean ejection fraction of the patients was 50±4.5.Single-vessel disease was present in 47 (31%) and 103 (69%) had multi-vessel disease. The mean NT-proBNP level in single-vessel disease was 561.34 pg/mL, and in multi-vessel disease, it was 1640.65 pg/mL. Raised levels of NT-proBNP were significantly associated with the severity of coronary artery disease. (P-value

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →